2024
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM
Khera R, Aminorroaya A, Dhingra L, Thangaraj P, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand T, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr D, Duarte-Salles T, DuVall S, Falconer T, French T, Hanchrow E, Kaur G, Lau W, Li J, Li K, Liu Y, Lu Y, Man K, Matheny M, Mathioudakis N, McLeggon J, McLemore M, Minty E, Morales D, Nagy P, Ostropolets A, Pistillo A, Phan T, Pratt N, Reyes C, Richter L, Ross J, Ruan E, Seager S, Simon K, Viernes B, Yang J, Yin C, You S, Zhou J, Ryan P, Schuemie M, Krumholz H, Hripcsak G, Suchard M. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM. Journal Of The American College Of Cardiology 2024, 84: 904-917. PMID: 39197980, DOI: 10.1016/j.jacc.2024.05.069.Peer-Reviewed Original ResearchConceptsGLP-1 RAsSecond-line agentsGLP-1Antihyperglycemic agentsCardiovascular diseaseMACE riskGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsEffects of SGLT2isType 2 diabetes mellitusPeptidase-4 inhibitorsAdverse cardiovascular eventsCox proportional hazards modelsRandom-effects meta-analysisCardiovascular risk reductionTarget trial emulationProportional hazards model
2023
Ocular complications of plasma cell dyscrasias
Singh R, Singhal S, Sinha S, Cho J, Nguyen A, Dhingra L, Kaur S, Sharma V, Agarwal A. Ocular complications of plasma cell dyscrasias. European Journal Of Ophthalmology 2023, 33: 1786-1800. PMID: 36760117, PMCID: PMC10472748, DOI: 10.1177/11206721231155974.Peer-Reviewed Original ResearchConceptsPlasma cell dyscrasiaMonoclonal gammopathyMultiple myelomaMalignant plasma cellsEfficacious treatment strategiesSearch of PubMedOcular presentationOcular complicationsTreating ophthalmologistClinical suspicionAsymptomatic patientsOphthalmological signsWaldenstrom's macroglobulinemiaSystemic findingsOphthalmologic disordersPre-malignantUnderlying diseasePosterior segmentPlasma cellsSkin changesTreatment strategiesOver-secretionEarly diagnosisCochrane DatabaseSystemic amyloidosis